Thomas Stephen Basil 4
4 · Eliem Therapeutics, Inc. · Filed Jun 27, 2024
Insider Transaction Report
Form 4
Thomas Stephen Basil
Director
Transactions
- Award
Common Stock
2024-06-27+103,907→ 103,907 total - Award
Restricted Stock Units
2024-06-27+100,375→ 100,375 total→ Common Stock (100,375 underlying)
Footnotes (3)
- [F1]The Reporting Person acquired 103,907 shares of the issuer's common stock in exchange for 838,000 shares of common stock of Tenet Medicines, Inc. ("Tenet") in connection with the issuer's acquisition of all of the outstanding common stock of Tenet on June 27, 2024 (the "Acquisition"). On the effective date of the Acquisition, the closing price of the issuer's common stock was $7.53 per share.
- [F2]Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon vesting.
- [F3]The RSUs were granted on June 27, 2024 and will vest as to 50% of the shares on January 1, 2025, as to 25% of the shares on March 27, 2025 and as to the remaining 25% of the shares on June 27, 2025, subject to the Reporting Person's continued service.